Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery

More than 20 Podium Presentations, Posters and Films to be Featured

LAVAL, Quebec, April 11, 2018 /CNW/ -- Bausch + Lomb, a leading global eye health company  and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), will present more than 20 new scientific data presentations, including 17 podium presentations and three posters, at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., from April 13-17, 2018.

"The breadth of data being presented at the ASCRS this year reinforces our commitment to investing in research across the Bausch + Lomb business, one of our core therapeutic areas of focus," said Joseph C. Papa, chairman and CEO, Valeant. "We are committed to the continued advancement of our eye health offerings to meet the needs of our customers and their patients."

A wet lab at the company's booth, as well as educational programs, will also provide opportunities for surgeons to gain firsthand experience with, and learn more about, Bausch + Lomb technologies. These include the company's latest next-generation platform for cataract and retina surgery, Stellaris Elite™ vision enhancement system, the VICTUS^® femtosecond laser for advanced cataract and corneal applications, and its broad selection of intraocular lenses (IOLs) and delivery systems, including the new enVista® MX60E with StableFlex™ technology.

The full schedule research to be presented includes:

Saturday, April 14

• Sheppard, John D. "Thirty-Six Month Clinical Experience with a Hydrophobic Acrylic IOL in Patients with Endothelial Compromise Undergoing Simultaneous Cataract Extraction and DSEK." Saturday, April 14 at 4:15 p.m.; Level 1, Room 144C
• Shultz, Mitchell C. "Analysis of Optical Aberrations and Depth of Focus Using a Ray-Tracing Analyzer in Patients with Zero Spherical Aberration IOLs." Saturday, April 14 at 1:07 p.m.; Level 1, Room 143B

Sunday, April 15

• Koch, Douglas D. "Evaluation of a New Phacoemulsification Infusion System."  Sunday, April 15 at 3:25 p.m.; Level 1, Room 143B
• McCabe, Cathleen M. "Phaco Energy Profile of Various Nuclear Disassembly Techniques in the Setting of Adaptive Fluidics." Sunday, April 15 at 3:02 p.m.; Level 1, Room 143B
• McCabe, Cathleen M. "Intraoperative Evaluation of New Vacuum-Based Phaco System with Adaptive Fluidics." Sunday, April 15 at 3:45 p.m.; Level 1, Room 143B
• Packer, Mark. "Comparison of Spectacle Independence for a New Toric Intraocular Lens (IOL) versus Predicate Spherical IOL." Sunday, April 15 at 8:51 a.m.; Level 1, Room 143A
• Packer, Mark. "Modeling the Effect of Off-Axis Light for Refractive and Diffractive IOLs." Sunday, April 15 at 8:45 a.m.; Level 1, Room 143C
• Shultz, Mitchell C. "Comparative Analysis of Dual Linear Phacoemulsification Using New Adaptive Fluidics System in Femtosecond-Assisted and Traditional Cataract Surgery." Sunday, April 15 at 3:07 p.m.; Level 1, Room 143B
• Shultz, Mitchell C. "Comparative Analysis of Dual Linear Phacoemulsification with New Adaptive Fluidics System in Traditional Phacoemulsification of Various Nuclear Densities." Sunday, April 15 at 3:17 p.m.; Level 1, Room 143B

Monday, April 16

• Jackson, Mitchell A. "Advantages of Multiburst Phaco Modality in Femtosecond Laser-Assisted Cases." Monday, April 16 at 3:41 p.m.; Level 1, Room 143A
• Liang, Eva I. "Comparison of Visual Outcomes of a Toric Accommodating IOL and a Toric Extended-Depth-of Focus IOL." Monday, April 16 at 8:17 a.m.; Level 1, Room 143B
• Liang, Eva I. "Patient Selection and Comparison of Visual Outcomes of an Accommodating IOL and an Extended-Depth-of-Focus IOL." Monday, April 16 at 8:43 a.m.; Level 1, Room 143B
• Sheppard, John D. "Twelve-Month Clinical Experience with a Hydrophobic Acrylic IOL in Patients at Risk for Intraocular Inflammation." Monday, April 16 at 3:12 p.m.; Level 1, Room 143C
• Vittitow, Jason L. "Efficacy and Safety of a Novel Submicron Corticosteroid Formulation in the Treatment of Inflammation and Pain Post-Cataract Surgery." Monday, April 16 at 1:46 p.m., Level 1, Room 143B
  

Tuesday, April 17

• Rowen, Sheri L. "Surgical Outcomes for Accommodative Intraocular Lens (IOL) in Patients with Highly Aberrated Corneas." Tuesday, April 17 at 11:08 a.m.; Level 1, Room 143C
• Stephenson, P. Dee G. "Clinical Evaluation of a New Material for Hydrophobic Acrylic IOL." Tuesday, April 17 at 11:03 a.m.; Level 1, Room 144B
• Whitman, Jeffrey. "Postoperative Aberration Profile After Implantation of Hinged, Plate-Haptic Accommodating IOL." Tuesday, April 17 at 10:51 a.m.; Level 1, Room 143C

Posters

• Lu, Kenneth. "Using Pattern ERG to Objectively Measure Contrast Sensitivity in Pseudophakes with Different IOLs." Poster available Saturday, April 14 to Tuesday, April 17
• O'Brien, Terrence P. "Manual versus Femtosecond Corneal Incisions." Poster available Saturday, April 14 to Tuesday, April 17
• Singh, Inder P. "Topology Verification of Femtosecond-Created Capsulorhexis and Arcuate Incisions Using Intraoperative Guidance System." Poster available Saturday, April 14 to Tuesday, April 17
  

Films

• Shultz, Mitchell C. "Adaptive Fluidics in Femtosecond Laser–Assisted Cataract Surgery." Film available Saturday, April 14 to Tuesday, April 17

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.valeant.com.

Forward-looking Statements
This news release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Valeant's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates. Any other product/brand names are trademarks of the respective owners.
© 2018 Bausch & Lomb Incorporated.

SOURCE Valeant Pharmaceuticals International, Inc.

Related Links

http://www.valeant.com